Game Changing Signals from Global Regulatory Agencies Accompany IVRO Sales and Profit Gains
Rhea-AI Summary
InVitro International (OTCQB: IVRO) reported FY 2025 sales of $878,937, a rise of 8.3% versus FY 2024, and net income of $121,980, up 14.3% year‑over‑year.
Management highlighted global regulatory developments saying some Regulatory Agencies have already, or will soon, cease funding animal testing and that certain agencies indicated OECD‑validated non‑animal test results could be accepted immediately. The company positions its in vitro test methods for large end markets including cosmetics, chemical companies, and adhesives manufacturers.
Positive
- Net income +14.3% YoY in FY 2025
- FY 2025 sales $878,937 (up 8.3% YoY)
- Company offers OECD‑validated non‑animal test methods
Negative
- FY 2025 sales remain under $1,000,000
- Sales growth +8.3% YoY (single‑digit increase)
News Market Reaction
On the day this news was published, IVRO gained 1.08%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Among key peers, only IDXG showed a similar gain at 8.09%, while others were flat. IVRO’s 9.47% rise with very low volume suggests a largely stock-specific reaction rather than a broad Diagnostics & Research move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Full-year results | Positive | +1.1% | FY 2025 sales and net income growth plus supportive regulatory signals. |
| Aug 05 | Quarterly results | Positive | +37.3% | Strong Q3 and YTD growth with growing support for in vitro testing. |
Recent positive operational and regulatory updates have coincided with positive next-day price reactions, including one notably strong move.
This announcement reports FY 2025 sales of $878,937, up 8.3%, and net income of $121,980, up 14.3%, alongside favorable global shifts away from animal testing. Earlier, on Aug 05 2025, IVRO highlighted Q3 FY ’25 momentum with sales of $234,430, up 39.7%, year-to-date sales of $675,080 (up 14.4%), and net income of $95,556 (up 17.1%). Both updates emphasized growing regulatory and customer support for in vitro methods, framing today’s news as a continuation of that trajectory.
Market Pulse Summary
This announcement highlights FY 2025 sales of $878,937, up 8.3%, and net income of $121,980, up 14.3%, alongside signals from global Regulatory Agencies reducing funding for animal testing and accepting OECD‑validated non‑animal methods. Earlier in FY ’25, IVRO also reported strong Q3 and year‑to‑date growth. Investors may monitor how quickly these regulatory shifts translate into demand from cosmetics, chemical, and adhesives customers, as well as changes in trading liquidity versus the 32,967 share average.
Key Terms
otcqb financial
regulatory agencies regulatory
oecd regulatory
in vitro testing medical
AI-generated analysis. Not financial advice.
Placentia, California--(Newsfile Corp. - December 9, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25 sales of
CEO and Chairman, W. Richard Ulmer, offered his view of IVRO's progress: "In this past year, Regulatory Agencies around the world announced they have already, or will soon, cease funding for animal testing; some have stopped now. Further, some RA's state OECD validated NON-animal test results could be accepted immediately. IVRO offers such test methods & serves large industries such as cosmetics, chemical companies, and varieties of adhesives manufacturers, globally. Our now 40-year-old vision for industry movement from animal databased safety testing to in vitro testing appears on its way to reality."
About InVitro International, Inc.
InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology driven provider of non-animal testing methods. The Company's testing technologies are designed to produce Regulatory Agencies' approved data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.
This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update such statements.
Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277330